Luminex DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand DiaSorin posted Q2 molecular revenues of €69.4 million, up 23 percent year over year from €56.6 million. DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence Premium DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio. DiaSorin to Acquire Luminex for $1.8B DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2 The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets. Feb 25, 2021 Luminex Shares Surge on Rumor of Acquisition by DiaSorin Feb 19, 2021 Luminex Nabs $11.3M From BARDA to Develop Test for SARS-CoV-2, Flu, RSV Feb 9, 2021 Luminex Moving Ahead With EUA Applications Despite Deprioritization of SARS-CoV-2 Test Submission Premium Feb 8, 2021 Luminex Q4 Revenues Rise 23 Percent; FDA Deprioritizes EUA Submission for COVID-19 Test Jan 14, 2021 JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More Jan 12, 2021 Luminex Preliminary Q4 Revenues Increase 23 Percent on MDx Strength Nov 5, 2020 Luminex Q3 Revenues Rise 35 Percent on Coronavirus Testing Demand Oct 7, 2020 Luminex Preliminary Q3 Revenues Rise 35 Percent on Pandemic-Related Demand Sep 8, 2020 As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza Premium Aug 27, 2020 As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit Aug 5, 2020 Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing Premium Aug 4, 2020 Luminex Q2 Revenues Rise 32 Percent on Pandemic-Related Sales Jul 8, 2020 Luminex Preliminary Q2 Revenues Rise More Than 30 Percent on Pandemic-Related Sales Jun 30, 2020 FDA Issues Warning Letter to Luminex Jun 1, 2020 Fluidigm Leads May GenomeWeb Index on Early Detection SARS-Cov-2 Blood Test Collaboration Details May 8, 2020 Luminex Prices $260M Senior Notes Offering May 4, 2020 Luminex Q1 Revenues Rise 10 Percent Apr 13, 2020 Coronavirus Tests From Seegene, DiaSorin, Others Get Health Canada Approval Apr 6, 2020 Luminex Preliminary Q1 Revenues Rise 10 Percent Apr 6, 2020 Luminex Receives FDA Emergency Use Authorization for Second SARS-CoV-2 Assay Load More Breaking News Bruker Posts 34 Percent Jump in Q2 Revenues GenomeWeb Index Gains Slightly in July as Fluidigm, PerkinElmer, Bio-Rad Post Strong Increases Feinstein Institutes for Medical Research Wins $2.9M NIH Grant to Study Polygenic Embryo Screening Top Five Articles on GenomeWeb Last Week: CDC, Bio-Rad, 10x Genomics, PerkinElmer, and More InterVenn Biosciences Closes $201M Series C Round Abcam to Acquire Life Science Research Tool Firm BioVision for $340M The Scan And Back The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database. Lacks Family Hires Attorney A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports. For the Unknown The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona. PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.